No, that was Aduhelm. Leqembi slows decline by 29%, more so in tau-negative subpopulations. https://investors.biogen.com/news-releases/news-release-details/eisa

No, that was Aduhelm. Leqembi slows decline by 29%, more so in tau-negative subpopulations. https://investors.biogen.com/news-releases/news-release-details/eisai-presents-full-results-lecanemab-phase-3-confirmatory https://investors.biogen.com/news-releases/news-release-deta...